Glenmark Life Sciences Ltd
NSE:GLS
Glenmark Life Sciences Ltd
Income from Continuing Operations
Glenmark Life Sciences Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
G
|
Glenmark Life Sciences Ltd
NSE:GLS
|
Income from Continuing Operations
₹4.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
₹55.8B
|
CAGR 3-Years
43%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
₹41.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
11%
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
₹90B
|
CAGR 3-Years
67%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Income from Continuing Operations
₹29.5B
|
CAGR 3-Years
19%
|
CAGR 5-Years
8%
|
CAGR 10-Years
13%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
₹15B
|
CAGR 3-Years
8%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
See Also
What is Glenmark Life Sciences Ltd's Income from Continuing Operations?
Income from Continuing Operations
4.7B
INR
Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Income from Continuing Operations amounts to 4.7B INR.
What is Glenmark Life Sciences Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
19%
Over the last year, the Income from Continuing Operations growth was 1%. The average annual Income from Continuing Operations growth rates for Glenmark Life Sciences Ltd have been 10% over the past three years , 19% over the past five years .